Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Post-ASCO 2024 GU Cancer Highlights
20 June 2024 | Virtual Meeting
Presentation summaries of key GU cancer abstracts from ASCO 2024 featuring panel discussions with leading experts
Updates in penile and prostate cancer
HERCULES: pembro + pt-based chemo in advanced penile cancer
Fernando Maluf Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil
CHAARTED2 Cabazitaxel + abiraterone vs abiraterone for extensive disease following docetaxel
Christos Kyriakopoulos University of Wisconsin, Madison, WI, United States
CYCLONE 2: abemaciclib + abiraterone for mCRPC
Josep Maria Piulats Bellvitge Biomedical Research Institute, Barcelona, Spain
PSMAfore: 177Lu-PSMA-617 vs. ARPI for mCRPC
Michael Morris Memorial Sloan Kettering Cancer Center, New York City, NY, United States
Session 1 panel discussion
Updates in bladder and kidney cancer
SURE-01/02: sacituzumab govitecan + pembro vs sacituzumab govitecan alone for MIBC
Antonio Cigliola San Raffaele Institute, Milan, Italy
CheckMate 901: nivo + GC vs. GC alone for mUC
Guru Sonpavde AdventHealth Cancer Institute, Orlando, FL, United States
KEYNOTE-426: pembrolizumab + axitinib vs sunitinib for RCC
Brian Rini Vanderbilt-Ingram Cancer Center, Nashville, TN, United States
Session 2 panel discussion
Assessing patient‐reported outcomes and quality of life in GU cancers
PSMAfore: HRQoL in study of [177Lu]Lu-PSMA-617 for CRPC
Michael Morris Memorial Sloan Kettering Cancer Center, New York City, NY, United States
EMBARK: post-hoc analysis of the impact of TxS on HRQoL
Stephen Freedland Cedars-Sinai Medical Center, Los Angeles, CA, United States
Session 3 panel discussion
